lunes, 2 de octubre de 2023

Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection: a prospective nationwide cohort study in the United States

https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(23)00140-0/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=276355044&_hsenc=p2ANqtz--YWYx3OpzNdp28mjB1ttqsJh6sz4BUb2S7PMkjFDX1eDM7HIub97O5AzSWJekDVqfvjCF_vE5AY_Xm1Gi22uoabo1_8w&utm_content=276317812&utm_source=hs_email

No hay comentarios: